Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
We’re the world’s leading provider of drug, device, company, clinical trial and market intelligence in the competitive pharma and medtech markets.
We provide unrivalled and daily-updated global insight, drawn from extensive authoritative data sets and enriched by human validation.
Our premium quality data is drawn from 42,000 companies, 248,000 clinical trials in 175 countries and 65,000 drugs for 1,400 diseases.
Our bespoke clinical, commercial and market access solutions are designed to help you make smarter decisions that bring a better return on investment.
Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.
We’re the trusted partner of more than 3,000 companies including the top 50 pharma firms and top 10 contract research organizations.
Our customer services team will support you every step of the way so that our insight, intelligence and bespoke solutions match your needs.
From single reports and data downloads to enterprise subscriptions to custom consultancy, we can base our precise solutions round your exact needs.
Get coverage of the latest pharmaceutical business developments, and historical metrics on financing, licensing, partnership, and acquisition.
Our trusted Pharma Intelligence brands
Scrip
By John Davis 20 Apr 2018
The sale of the Merck KGaA consumer health business to Procter & Gamble could eventually give the German multinational greater flexibility in business development activities, but reducing net debt has first claim on the funds.
Scrip
By Mike Ward 20 Apr 2018
Denoive acquires from TVM Capital both Biovertis and Morphochem, plus a Phase II ready antibiotic asset, for an initial 4% stake worth €900,000. Since their formation, Biovertis and Morphochem have had more than $96m invested in them.
Datamonitor Healthcare
15 Apr 2018
Zach McLellan, Jack Allen, and guest analyst Michael Ramirez discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including the Novartis purchase of AveXis for $8.7 billion as they target gene therapy in SMA.
Topic Company analysis
Biomedtracker
13 Apr 2018
What’s on the horizon for pharma in 2018? Find out with Biomedtracker’s Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.
Pharmaprojects
By Ian Lloyd 11 Apr 2018
Will the Pharma R&D Annual Review 2018 from Citeline’s Pharmaprojects be music to your ears, or will it sound a sour note? Find out with the Pharma R&D Annual Review 2018 infographic, now available to you as a free download.
Pharmaprojects
By Ian Lloyd 10 Apr 2018
You’ve already tuned into Pharma R&D Annual Review 2018, the free, music-themed whitepaper from Citeline’s Pharmaprojects. Now, get even more free market data and insights with your download of Pharma R&D Annual Review 2018 Supplement: New Active Substances Launched During 2017.
Datamonitor Healthcare
By Jack Allen 09 Apr 2018
Zach McLellan & Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including analysis on Allogene's announcement that they are in-licensing the TALEN technology from Pfizer to commericalise and develop allogeneic, potentially leading to a strong acceleration of CART therapies.
In Vivo
By Ashley Yeo 08 Apr 2018
The leading medtechs are starting to develop models for providers that show how to implement successful digital strategies, a trend that is serving to put pressure on companies that are yet to make a commitment, says ZS Associates' Pete Masloski.
Topic Digital Health
Scrip
By Mandy Jackson 06 Apr 2018
Offerings by Homology, Unum and Genprex at the end of March brought the first quarter's biopharma IPO total to 14 in the US, putting 2018 on track to beat the 2017 total of 42. But with the average return for this year's IPOs dropping, the pace of offerings could slow.
Topic Company analysis
Scrip
By Jessica Merrill 06 Apr 2018
CEO Richard Pops called FDA's letter for ALKS 5461 "surprising and troubling." Alkermes had been ramping up to launch the depression drug later this year, though some investors had remained skeptical.
Topic FDA Drug approval
Datamonitor Healthcare, Biomedtracker
05 Apr 2018
To beat your competition, turn to the combined power of Biomedtracker and Datamonitor Healthcare for the most reliable and timely information in the industry.
Topic Drug review
Biomedtracker
05 Apr 2018
For a look at the outcome of two catalysts featured in Biomedtracker’s Q4 2017 Outlook Report, download the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report.
Biomedtracker
05 Apr 2018
Don't miss out on this comprehensive review of all the presentations from the conference, complied by our analysts, with key points and expert insight, for you to download, for free. A full list of events and catalysts that were announced or updated during the conference is included in this report.
Topic Strategy
Pharmaprojects, Citeline
By Ian Lloyd 05 Apr 2018
Authored for the last 25 years by Ian Lloyd, Senior Director of Pharmaprojects and Data Integration, this vital resource uses a music motif to turn up the volume on the evolution of trends in pharmaceutical R&D. Lloyd assesses industry trends by examining the pipeline by company, therapeutic area, disease, target, and drug type.
Topic Research
Scrip
By Mandy Jackson 29 Mar 2018
GSK removed some uncertainty about how much it could invest in pharma R&D and business development by purchasing Novartis' share of the firms' Consumer Healthcare Joint Venture. Now it can more accurately allocate capital as it prepares for battle in HIV and braces for Advair generics.
Topic Business strategies
Scrip
23 Apr 2018
Medtech Insight
23 Apr 2018
Scrip
23 Apr 2018
Scrip
23 Apr 2018
Medtech Insight
23 Apr 2018
Medtech Insight
23 Apr 2018
Scrip
23 Apr 2018
Scrip
23 Apr 2018
Medtech Insight
23 Apr 2018
Pink Sheet
23 Apr 2018
Pink Sheet
22 Apr 2018
Scrip
21 Apr 2018
Pink Sheet
21 Apr 2018
Pink Sheet
21 Apr 2018
Pink Sheet
21 Apr 2018
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Key benefits:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Key benefits:
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
